静息期系统性红斑狼疮患者停用抗疟药后的结局
研究纳入1573例使用抗疟药的SLE患者,其中165例达到临床缓解至少1年后停用抗疟药,96例有充分随访,88例成功匹配1名对照、85例匹配2名对照共173名对照。停药组复发率61.4%高于对照组45.1%(p=0.002),逐渐减量者复发率45.9%低于突然停药者72.6%(p=0.01)。
要点
- 停用抗疟药者复发率61.4%,高于继续用药者的45.1%(p=0.002)。
- 停药后52.3%因疾病复发重新用药,其中88%恢复控制或改善,12%未恢复。
- 逐渐减量者复发率45.9%,低于突然停药者的72.6%(p=0.01)。
核心结论
- 抗疟药有助于预防疾病复发,即使患者已获得长期临床缓解。
- 逐渐减量抗疟药可降低复发率。
- 作者认为,除毒性反应情况外,长期疾病静息患者停用抗疟药采用缓慢减量是可行的。
研究设计与样本
- 研究比较了达到临床缓解至少1年后停用抗疟药的SLE患者与继续用药的对照者的复发率,并比较逐渐减量与突然停药者的复发率。
- 停药组为达到临床缓解至少1年后完全停用抗疟药者,指标日期定义为完全停用抗疟药之日。
- 对照为达到临床缓解至少1年且继续使用抗疟药者,按缓解前抗疟药使用时长及从缓解日至病例指标日的治疗时长进行匹配。
- 所有患者随访至少2年。
- 1573例使用抗疟药的患者中,165例达到1年缓解后停用抗疟药,96例有充分随访,88例成功匹配1名对照,85例匹配2名对照,共173名对照。
主要发现
- 停药组复发率为61.4%,对照组为45.1%(p=0.002)。
- 停用抗疟药的患者中52.3% later因疾病复发重新使用抗疟药。
- 重新用药者中88%恢复控制或改善,12%未恢复。
- 逐渐减量者复发率45.9%,突然停药者复发率72.6%(p=0.01)。
关键数值与推荐
- 停药组复发率61.4% vs 对照组45.1%(p=0.002)。
- 停药后因复发重新用药者占52.3%。
- 重新用药后88%恢复控制或改善,12%未恢复。
- 逐渐减量者复发率45.9% vs 突然停药者72.6%(p=0.01)。
临床怎么用
- 作者认为,除毒性反应情况外,长期疾病静息患者停用抗疟药采用缓慢减量是可行的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antimalarial medications (AMs) are central to the management of SLE. We investigated the rate of flare in lupus patients who withdrew AM after achieving clinical remission for at least one year, compared to those who continued therapy and compared flare rates in cases who tapered AM versus abruptly withdrew. METHODS: Cases achieved clinical remission for at least one year then ceased their AM. Index date was defined as the date of complete AM cessation. Controls achieved clinical remission for at least one year and continued AM. Controls were matched according to the duration of AM before remission and the duration of therapy from remission date to case index date. All patients had ≥ 2 years of follow up. RESULTS: Of 1573 patients on AM, 165 achieved a one-year remission and then ceased their AM. 96 had adequate follow-up, 88 were successfully matched to one control and 85 to 2 controls for a total of 173 controls. Flare occurred in 61.4% of cases and 45.1% of controls (p = 0.002). 52.3% patients who withdrew AM later restarted it due to disease flare. 88% recaptured control or improved, while 12% did not. Patients who tapered had significantly fewer flares (45.9% vs. 72.6%; p = 0.01). CONCLUSION: AMs aid in preventing disease flare even in patients who have achieved prolonged clinical remission. Tapering AM results in lower flare rates. Hence, except in the setting of toxicity, cessation of antimalarial therapy in patients with prolonged disease quiescence is feasible using a slow taper.
引用
- Papachristos DA, Gladman DD, Su J, et al. Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. Semin Arthritis Rheum. 2022. PMID: 35716465. doi:10.1016/j.semarthrit.2022.152046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。